financetom
Business
financetom
/
Business
/
WW Grainger cuts 2024 sales forecast on slow demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
WW Grainger cuts 2024 sales forecast on slow demand
Aug 1, 2024 6:37 AM

Aug 1 (Reuters) - Industrial maintenance and safety

products supplier WW Grainger Inc ( GWW ) on Thursday lowered

its annual sales forecast due to slower-than-expected demand,

sending its shares down 4% in premarket trading.

The Lake Forest, Illinois-based company now expects 2024

sales to be between $17 billion and $17.3 billion, down from its

previous forecast of $17.2 billion to $17.7 billion, issued in

April.

The company provides hand tools, power tools and industrial

products to home improvement retailers, construction businesses

and aerospace manufacturers.

Second-quarter sales for the company, which competes with

Fastenal ( FAST ) and WESCO, rose 3.1% to $4.31 billion.

Adjusted per-share earnings for the quarter ended June 30

was $9.76, up from $9.28 a year earlier.

The stock until the last close had gained 18% so far this

year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer
Apr 15, 2024
05:00 PM EDT, 04/15/2024 (MT Newswires) -- ORIC Pharmaceuticals ( ORIC ) said late Monday it dosed the first patients in three dose expansion groups in a phase 1b trial of ORIC-114 in people with lung cancer. The phase 1b expansion part of the study will assess the safety and efficacy of the candidate drug at the provisional recommended phase...
Progress Software Insider Sold Shares Worth $1,020,000, According to a Recent SEC Filing
Progress Software Insider Sold Shares Worth $1,020,000, According to a Recent SEC Filing
Apr 15, 2024
04:56 PM EDT, 04/15/2024 (MT Newswires) -- David Krall, Director, on April 11, 2024, sold 20,000 shares in Progress Software ( PRGS ) for $1,020,000. Following the Form 4 filing with the SEC, Krall has control over a total of 86,641 shares of the company, with 86,641 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/876167/000087616724000082/xslF345X03/wk-form4_1713214338.xml ...
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial
Apr 15, 2024
04:58 PM EDT, 04/15/2024 (MT Newswires) -- Edgewise Therapeutics ( EWTX ) said late Monday that an open-label trial of sevasemten in adults with Becker muscular dystrophy showed positive two-year topline results. Sevasemten was well-tolerated in 12 participants with no adverse event-related discontinuation or dose reductions, the firm said. The results from the trial further support the hypothesis that a...
Real estate commission antitrust settlements face legal objections
Real estate commission antitrust settlements face legal objections
Apr 15, 2024
April 15 (Reuters) - One of the country's largest residential homebuilders has asked a U.S. judge not to approve $208 million in settlements resolving claims that major home brokerages conspired to keep real estate commissions artificially high. Atlanta-based homebuilder PulteGroup ( PHM ) in a filing on Friday questioned the adequacy of the proposed deals, which would resolve antitrust claims...
Copyright 2023-2026 - www.financetom.com All Rights Reserved